Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.55 |
| ▸ | GRM4 | Q14833 | 5/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.52 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | BCR | P11274 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6885328 | 0.95 | KDR (0.55) | KDRGRM4HDAC6KCNK3KCNK9 | |
| SCHEMBL6889061 | 0.94 | GRM4 (0.56) | KDRGRM4HDAC6KCNK3KCNK9 | |
| SCHEMBL6027211 | 0.89 | GRM4 (0.45) | KDRGRM4HDAC6KCNK3KCNK9 | |
| SCHEMBL1624812 | 0.80 | GRM4 (0.57) | GRM4HDAC6 | |
| SCHEMBL6030750 | 0.79 | RAB9A (0.62) | KDRGRM4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL31660405 | 0.79 | BACE1 (0.61) | KCNK3KCNK9BACE1NPC1RAB9A | |
| SCHEMBL26094468 | 0.79 | BACE1 (0.61) | KCNK3KCNK9BACE1NPC1RAB9A | |
| SCHEMBL15707580 | 0.78 | SCN2A (0.55) | GRM4HDAC6BACE1SMN1; SMN2SCN2A | |
| SCHEMBL19443319 | 0.78 | GRM4 (0.43) | GRM4BACE1SCN2A | |
| SCHEMBL19443380 | 0.78 | LMNA (0.48) | BACE1NPC1RAB9ASMN1; SMN2SCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1613310-A1 | IMIDAZOLE DERIVATIVES FOR TREATMENT OF ALLERGIC AND HYPERPROLIFERATIVE DISORDERS | Avanir Pharmaceuticals (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20040229927-A1 | Imidazole derivatives for treatment of allergic and hyperproliferative disorders | AVANIR PHARMACEUTICALS | 2004-11-18 | — | — | US | disclosed |
| WO-2004091610-A1 | IMIDAZOLE DERIVATIVES FOR TREATMENT OF ALLERGIC AND HYPERPROLIFERATIVE DISORDERS | AVANIR PHARMACEUTICALS (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229927-A1 | Imidazole derivatives for treatment of allergic and hyperproliferative disorders | ICOS, TSLP, IKZF3 | KDR 876/4885GRM4 4630/4885HDAC6 1515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.